We read with interest the paper by Stevens et al. [1] 
risk equations [3] , which are only interested in the presence or absence of diabetes. The inclusion of HbA "c as a continuous risk factor for CHD in Type II diabetes resulted in a significant increase in the 10-year risk.
The National Service Framework for CHD prevention proposed that statins should be limited to patients with a Correspondence   Table 1 Effect of measuring HDL cholesterol by the new methods on the 10-year CHD risk
The risk is calculated for a hypothetical 55-year-old patient with Type II diabetes and blood pressure 150/80 mmHg, using the computer program recommended by the Joint British Guidelines for CHD prevention. The HDL cholesterol (HDL-C) results were obtained using the regression equation relating results by the precipitation method and the homogeneous method marketed by Roche (see Figure 1) 
10-year CHD risk of 30 %, but the Joint British Guidelines for CHD prevention [4] recommended a staged progressive approach to extend drug therapy to patients with a 10-year risk of 15 %.
The UKPDS equation is capable of identifying more patients above the cut-off level of 30 % risk, but probably on average performs similarly to the Framingham risk equations when a cut-off level of 15 % is used [5] .
We would like to highlight another cause for bias in calculating CHD risk in Type II diabetes, that is the value of high-density lipoprotein (HDL) cholesterol.
HDL cholesterol is one of the risk factors included in risk calculation by both the UKPDS and the Framingham methods. Until recently, the common method for measuring HDL cholesterol was an indirect two-step procedure. This method involved the addition of divalent cations and polyanions for the precipitation of apoB-containing particles [very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL)], with subsequent cholesterol determination in the supernatant. These methods agree very well with the reference method, which depends on preparative ultracentrifugation [6] . However, these methods were laborious, using expensive staff time and are not amenable to automation, due to the need for centrifugation.
Several methods have now been introduced for the direct measurement of HDL cholesterol that is readily adaptable to automation procedures. The new methods are also called the homogeneous methods because all the reactions take place in one medium, without the need for separation by centrifugation. The homogeneous methods rely on masking or inactivating the VLDL and LDL, leaving only the HDL cholesterol available to react with cholesterol-measuring reagents. It is possible to automate these methods and make it easy to measure large numbers of HDL cholesterol levels cheaply. They have already replaced the conventional precipitation methods in most clinical laboratories.
We compared the performance of four homogeneous methods with the conventional precipitation method in groups of patients with Type I or Type II diabetes (30 in each group). The four methods are named in this study after the companies which market them as the Wako, Sigma, Roche and Randox methods.
The new homogeneous methods showed positive bias for patients with diabetes ( Figure 1) . However, in patients with Type I diabetes, the bias is small and the new homogeneous methods could probably be used safely. The bias in Type II patients is greater and becomes worse at low HDL cholesterol concentrations ( 0.9 mmol\l). Table 1 demonstrates the effect of such bias on the 10-year CHD risk calculated using the computer program recommended by the Joint British Guidelines for CHD prevention. It is evident from the Table that using the homogeneous HDL cholesterol methods is likely to lead to underestimation of the calculated CHD risk and may influence the decision for initiating lipid-lowering therapy in patients with Type II diabetes.
The homogeneous methods are here to stay because of their advantages. We propose that the value of HDL cholesterol measured by a homogeneous method be corrected to remove the positive bias before the value is used to calculate CHD risk. This could be done by incorporating the regression equation into risk calculators used for patients with Type II diabetes.
